Inhibrx Biosciences, Inc. · NASDAQ:INBX

Inhibrx Biosciences — ASCPT 2023

10 slides from Inhibrx Biosciences's conference presentation, March 2023

  1. Slide 1: INBRX-109 (DR5) dose selection: you must choose, but choose wisely

    INBRX-109 S. Bhagwat1, C. Veldstra1, B. Eckelman1, K. Willis1, C. Bais1, V. Andrianov1, K. Bayer1, J. Jensen1, K. Brown2, F. Engler3, A. (DR5) dose selection: Zandvliet4, Y. Lin5, J. Kalabus1 you must choose, but 1Inhibrx, San Diego, CA, USA 2Certara, London, England, United Kingdom, 3Certara, choos

  2. Slide 2: Death receptor 5 (DR5) target overview

    Death receptor 5 (DR5) target overview Death receptor 5 (DR5) is a receptor for the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) DR5 activation naturally eliminates damaged and/or neoplastic cells Normal cells are less sensitive to DR5- mediated cell death Higher order clustering

  3. Slide 3: Valency drives DR5-mediated apoptosis

    Valency drives DR5-mediated apoptosis % Cancer Cell Viability Concentration (nM) INBRX-109 is ~100x more potent in preclinical assays compared to first generation bivalent and trivalent agonists 3

  4. Slide 4: INBRX-109 activity was characterized using preclinical and clinical data

    INBRX-109 activity was characterized using preclinical and clinical data • In vitro assays for evaluation of mechanism of action • In vivo mouse and cynomolgus monkey models for understanding of drug behavior - PK: Pharmacokinetics (INBRX-109 drug exposure) Preclinical - Drug levels achieved as meas

  5. Slide 5: Key challenge for dose selection: bell-shaped response

    Key challenge for dose selection: INBRX-109 bell-shaped response is crucial to unlocking optimal anti-cancer potential Across in vivo and in vitro preclinical studies where INBRX-109 was active, a bell-shaped dose activity relationship was observed Doses/exposures on either side of the bell ranged f

  6. Slide 6: INBRX-109 Preclinical PK/PD Model Structure with Bell-Shaped Dose Response

    INBRX-109 Preclinical PK/PD Model Structure with Bell-Shaped Dose Response !"#$%&(() +"#$%&(() S(t) = !& *&(() − +&!" *&(() !" • The drug action function can be interpreted as two opposing processes with sensitivity parameters EC50 (concentration at which maximal tumor killing is at 50%) and IC50 (c

  7. Slide 7: The proposed PK/PD model adequately described the xenograft data

    The proposed PK/PD model adequately described the xenograft data Parameter (unit) Estimate RSE% Shrinkage (%) kg (1/hr) 0.00245 3.5% - kt (1/hr) 0.0269 13.2% - EC50 (µg/mL) 1.25 14.0% - Model indicates effective INBRX-109 IC50 (µg/mL) 88.9 20.8% - Tss (mm3) 2290 4.2% - concentration range is 1.25 –

  8. Slide 8: INBRX-109 PK approximately dose proportional in FIH clinical study

    In the FIH clinical study, INBRX-109 PK was approximately dose proportional across the range of doses administered in the study (0.03 – 30 mg/kg) 8

  9. Slide 9: Two-compartment model with linear elimination characterized clinical PK

    A two-compartment model with linear elimination was used to characterize the clinical PK Goodness-of-fit plots for the final INBRX-109 population PK model showed the model adequately fit the data with no unacceptable trends 9

  10. Slide 10: PopPK model simulated exposure at the RP2D regimen of 3 mg/kg every 3 weeks

    The final clinical popPK model was applied to simulate the INBRX-109 exposure at the RP2D dosing regimen of 3 mg/kg every 3 weeks Predicted human exposures following 3 mg/kg Q3W IV infusions were anticipated to fall predominantly within the efficacious concentration range of 1.25 – 88.9 µg/mL Figure

Inhibrx Biosciences — ASCPT 2023 on 6ix